Oxymetholone is generally assumed to be a nongenotoxic carcinogen. This assumption is based primarily on the results of an Ames test, existing data in repeat-dose toxicology studies, and the predicted results of a 2-yr National Toxicology Program (NTP) rat carcinogenicity bioassay. To provide a comprehensive assessment of its genotoxicity in a standard battery of mutagenicity assays, oxymetholone was tested in microbial and mammalian cell gene mutation assays, in an in vitro cytogenetics assay (human lymphocytes), and in an in vivo micronucleus assay. Oxymetholone was also tested in an in vitro morphologic transformation model using Syrian hamster embryo (SHE) cells. These studies were initiated and completed prior to the disclosure of the results of the NTP bioassay. Oxymetholone was tested at doses up to 5,000 &mu;g/plate in the bacterial plate incorporation assay using 4 Salmonella strains and the WP2 uvrA (pKM101) strain of Escherichia coli. There was no induction of revertants up to the highest dose levels, which were insoluble as well as toxic. In the L5178Y tk +/-mouse lymphoma assay, doses up to 30 &mu;g/ml reduced relative survival to &sim;30% with no increase in mutants. Male or female human lymphocytes were exposed in vitro to oxymetholone for 24 hr without S9 or 3 hr with S9 and evaluated for the induction of chromosomal aberrations. There was no increase in aberration frequency over control levels and no difference between male and female cells. Peripheral blood from Tg.AC transgenic mice treated dermally for 20 wk with 0, 1.2, 6.0, or 12.0 mg/day of oxymetholone and from p53 transgenic mice treated orally by gavage for 26 wk with 125, 625, or 1,250 mg/kg/day of oxymetholone was evaluated for micronuclei in polychromatic and normochromatic erythrocytes. There was no difference in micronuclei frequency between control and treated animals. These results confirm that oxymetholone is not genotoxic in a comprehensive battery of mutagenicity assays. In the SHE assay, oxymetholone produced a significant increase in morphologically transformed colonies at dose levels of 13-18 &mu;g/ml. The lack of genotoxicity of oxymetholone, the positive response in the in vitro transformation assay, and the results of transgenic mouse carcinogenicity assays will provide an interesting perspective on the results of an on-going NTP rat carcinogenicity bioassay.
INTRODUCTION
Bootman (2) predicted that oxymetholone would prove to be carcinogenic in an on-going National Toxicology Program (NTP) rat bioassay (19) . This prediction was based on the promotor activity of oxymetholone and its classification as an anabolic steroid. Because of the current state of knowledge about the toxicity of oxymetholone, it was selected as an ideal candidate for prospective evaluation in 2 developmental transgenic mouse models for detecting carcinogenicity (9, 20) . Oxymetholone is also considered to be nongenotoxic. However, the only support of the nongenotoxic nature of oxymetholone has been a negative result reported in a Salmonella assay (22) . To 
RESULTS

Bacterial Mutation Assays
Testing of oxymetholone in bacteria had previously been reported by Zeiger et al. (22) . In that study, TA1535, TA97, TA98, and TA100 were tested using the preincubation modification of the bacterial mutation assay. The bacteria were treated either in the absence of an activation system or in the presence of an activation system from Aroclor 1254-induced rat or (Table II) . In the absence of an activation system (Table III) , lymphocytes were treated with oxymetholone for the last 24 hr over a dose range of 5-16 ~Lg/ml. At doses >14 )JLg/ ml, oxymetholone reduced the relative mitotic index to <50% that of the controls.
In the presence of an activation system (Table IV) , human peripheral blood lymphocytes were treated with oxymetholone for 3 hr over a dose range of 15-30 )JLg/ml (male donor) or 30-40 Rg/ml (female donor). Relative mitotic indices were reduced at doses ~30 ~,glml.
There was no significant increase in number of aberrant cells at any dose level under either test condition.
There was no apparent difference in the effects of oxymetholone on cells from a male versus female donor.
Micronucleus Assays
In the peripheral blood of Tg.AC mice treated dermally with vehicle or oxymetholone for 20 wk at dose levels (Table VI) .
In both studies, the positive control Mitomycin C, administered intraperitonealy for 3 days, decreased the PCE/NCE frequency and induced a significant (-10-fold) increase in MN-PCE.
SHE Assay
The pooled results of 3 separate assays are shown in Table VII . At ? 18 I-lg/ml, toxicity of the compound (reduced number of colonies per plate) precluded evaluation for transformation. At levels of 12-16.5 
